| Name | CC-99677 |
|---|---|
| Synonyms |
Gamcemetinib
Gamcemetinib (CC-99677) (R)-3-((2-Chloro-5-(ethoxymethyl)pyrimidin-4-yl)oxy)-10-methyl-9,10,11,12-tetrahydro-8H-[1,4]diazino[5',6':4,5]thieno[3,2-f]quinolin-8-one CC99677|||Gamcemetinib|||CC 8H-[1,4]Diazino[5',6':4,5]thieno[3,2-f]quinolin-8-one, 3-[[2-chloro-5-(ethoxymethyl)-4-pyrimidinyl]oxy]-9,10,11,12-tetrahydro-10-methyl-, (10R) (15R)-5-[2-chloro-5-(ethoxymethyl)pyrimidin-4-yl]oxy-15-methyl-11-thia-6,14,17-triazatetracyclo[8.8.02.0121]octadeca-1,2,3,5,8,12-hexaen-13-one (R)-3-((2-chloro-5-(ethoxymethyl)pyrimidin-4-yl)oxy)-10-methyl-9,10,11,12-tetrahydro-8H-[1,4]diazino[5',6':4,5]thieno[3,2-f]quinolin-8-one - [AC80524] |
| Description | CC-99677 is a potent, covalent, and irreversible inhibitor of the mitogen-activated protein (MAP) kinase-activated protein kinase-2 (MK2) pathway in both biochemical (IC50=156.3 nM) and cell based assays (EC50=89 nM). CC-99677 is extracted from patent WO2020236636, compound 1[1]. |
|---|---|
| Related Catalog | |
| Target |
MK2[1] |
| In Vitro | CC-99677 is a potent, covalent, and irreversible inhibitor of the mitogen-activated protein (MAP) kinase-activated protein kinase-2 (MK2) pathway in both biochemical (IC50=156.3 nM) and cell based assays (EC50=89 nM)[1]. |
| References |
[1]. WO2020236636 |
| Molecular Formula | C22H20ClN5O3S |
|---|---|
| Molecular Weight | 469.94 |